Blood biomarkers of response to concomitant intratympanic and systemic corticosteroids treatment for idiopathic sudden sensorineural hearing loss
- PMID: 41430443
- DOI: 10.1007/s00405-025-09904-w
Blood biomarkers of response to concomitant intratympanic and systemic corticosteroids treatment for idiopathic sudden sensorineural hearing loss
Abstract
Purpose: To evaluate the prognostic value of hematological inflammatory biomarkers in predicting hearing recovery in patients with idiopathic sudden sensorineural hearing loss (ISSNHL) treated with combined systemic and intratympanic corticosteroids.
Methods: This retrospective study included 125 patients diagnosed with ISSNHL between 2012 and 2021 who received both oral prednisone and intratympanic methylprednisolone. Clinical data and pre-treatment blood samples were collected. Inflammatory indices including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and systemic inflammation response index (SIRI) were calculated. Hearing outcomes were classified as complete, partial, or no recovery based on pure tone average (PTA) thresholds. Univariate and multivariable logistic regression analyses were performed to identify predictors of recovery.
Results: Of the 125 patients, 33 (26.4%) had no recovery, 50 (40.0%) partial recovery, and 42 (33.6%) complete recovery. Dizziness, current smoking, delayed treatment initiation (> 7 days), elevated triglycerides (≥ 98 mg/dL), and high PLR (≥ 142) were independently associated with a lower probability of hearing recovery. A higher LMR (≥ 3.0) showed a positive trend but did not reach statistical significance in adjusted models.
Conclusions: In patients with ISSNHL treated with dual-route corticosteroids, several clinical and hematologic factors, particularly elevated PLR and delayed treatment, are independently associated with reduced odds of hearing recovery. Inflammatory blood markers may serve as accessible prognostic tools to support early risk stratification.
Keywords: Corticosteroid therapy; Hearing recovery; Idiopathic sudden sensorineural hearing loss; Inflammatory biomarkers; Intratympanic injection; Platelet-to-lymphocyte ratio.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval: The study protocol was approved by the University of Trieste Ethics Committee on Clinical Investigation in compliance with the Helsinki Declaration. Informed consent: Additional informed consent was obtained from all individual participants for whom identifying information is included in this article. Conflict of interest: The authors declare that they have no conflicts of interest.
References
-
- Sudden Sensorineural Hearing Loss (SSHL) | NIDCD (2018) https://www.nidcd.nih.gov/health/sudden-deafness . Accessed 19 Feb 2024
-
- Alexander TH, Harris JP (2013) Incidence of sudden sensorineural hearing loss. Otol Neurotol 34:1586–9. https://doi.org/10.1097/MAO.0000000000000222 - DOI - PubMed
-
- Dallan I, Fortunato S, Casani AP, Bernardini E, Sellari-Franceschini S, Berrettini S et al (2014) Long-term follow up of sudden sensorineural hearing loss patients treated with intratympanic steroids: audiological and quality of life evaluation. J Laryngol Otol 128:669–73. https://doi.org/10.1017/S0022215114001595 - DOI - PubMed
-
- Lionello M, Tealdo G, Breda S, Giacomelli L, Staffieri A, Marioni G (2014) Idiopathic sudden sensorineural hearing loss in elderly patients: univariate and multivariate analysis of potential clinical prognostic factors. Hear Balance Commun 12:182. https://doi.org/10.3109/21695717.2014.965498 - DOI
-
- Chandrasekhar SS, Tsai Do BS, Schwartz SR, Bontempo LJ, Faucett EA, Finestone SA et al (2019) Clinical practice guideline: sudden hearing loss (Update). Otolaryngol Head Neck Surg 161(1_suppl):S1–45. https://doi.org/10.1177/0194599819859885 - DOI - PubMed
LinkOut - more resources
Full Text Sources
